These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 24462692)

  • 1. Molecular modeling and residue interaction network studies on the mechanism of binding and resistance of the HCV NS5B polymerase mutants to VX-222 and ANA598.
    Xue W; Jiao P; Liu H; Yao X
    Antiviral Res; 2014 Apr; 104():40-51. PubMed ID: 24462692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probing the "fingers" domain binding pocket of Hepatitis C virus NS5B RdRp and D559G resistance mutation via molecular docking, molecular dynamics simulation and binding free energy calculations.
    Manjula S; Sivanandam M; Kumaradhas P
    J Biomol Struct Dyn; 2019 Jun; 37(9):2440-2456. PubMed ID: 30047829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the drug resistance mechanism of hepatitis C virus NS5B to PF-00868554 due to mutations of the 423 site: a computational study.
    Jiao P; Xue W; Shen Y; Jin N; Liu H
    Mol Biosyst; 2014 Apr; 10(4):767-77. PubMed ID: 24452008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening of hepatitis C NS5B polymerase inhibitors containing benzothiadiazine core: a steered molecular dynamics.
    Nutho B; Meeprasert A; Chulapa M; Kungwan N; Rungrotmongkol T
    J Biomol Struct Dyn; 2017 Jun; 35(8):1743-1757. PubMed ID: 27236925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.
    Xue W; Ban Y; Liu H; Yao X
    J Chem Inf Model; 2014 Feb; 54(2):621-33. PubMed ID: 23745769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor.
    Jiang M; Zhang EZ; Ardzinski A; Tigges A; Davis A; Sullivan JC; Nelson M; Spanks J; Dorrian J; Nicolas O; Bartels DJ; Rao BG; Rijnbrand R; Kieffer TL
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5456-65. PubMed ID: 24982088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational study on the drug resistance mechanism of HCV NS5B RNA-dependent RNA polymerase mutants V494I, V494A, M426A, and M423T to Filibuvir.
    Wang H; Guo C; Chen BZ; Ji M
    Antiviral Res; 2015 Jan; 113():79-92. PubMed ID: 25449363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir.
    Yi G; Deval J; Fan B; Cai H; Soulard C; Ranjith-Kumar CT; Smith DB; Blatt L; Beigelman L; Kao CC
    Antimicrob Agents Chemother; 2012 Feb; 56(2):830-7. PubMed ID: 22143520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders.
    Eltahla AA; Tay E; Douglas MW; White PA
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7215-24. PubMed ID: 25246395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined 3D-QSAR, molecular docking, molecular dynamics simulation, and binding free energy calculation studies on the 5-hydroxy-2H-pyridazin-3-one derivatives as HCV NS5B polymerase inhibitors.
    Yu H; Fang Y; Lu X; Liu Y; Zhang H
    Chem Biol Drug Des; 2014 Jan; 83(1):89-105. PubMed ID: 23941500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allosteric mechanism of cyclopropylindolobenzazepine inhibitors for HCV NS5B RdRp via dynamic correlation network analysis.
    Rahman MU; Liu H; Wadood A; Chen HF
    Mol Biosyst; 2016 Oct; 12(11):3280-3293. PubMed ID: 27528077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular modeling study on the drug resistance mechanism of NS5B polymerase to TMC647055.
    Wang H; Cui W; Guo C; Chen BZ; Ji M
    Biochem Cell Biol; 2016 Apr; 94(2):147-58. PubMed ID: 26836778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase.
    Dvory-Sobol H; Voitenleitner C; Mabery E; Skurnac T; Lawitz EJ; McHutchison J; Svarovskaia ES; Delaney W; Miller MD; Mo H
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6599-606. PubMed ID: 25155588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Molecular Field Analysis and Molecular Docking Studies on Quinolinone Derivatives Indicate Potential Hepatitis C Virus Inhibitors.
    Malathi K; Ramaiah S; Anbarasu A
    Cell Biochem Biophys; 2019 Jun; 77(2):139-156. PubMed ID: 30796723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase.
    Kukolj G; McGibbon GA; McKercher G; Marquis M; Lefèbvre S; Thauvette L; Gauthier J; Goulet S; Poupart MA; Beaulieu PL
    J Biol Chem; 2005 Nov; 280(47):39260-7. PubMed ID: 16188890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insight into the structural requirements of benzothiadiazine scaffold-based derivatives as hepatitis C virus NS5B polymerase inhibitors using 3D-QSAR, molecular docking and molecular dynamics.
    Zhang HX; Li Y; Wang X; Xiao ZT; Wang YH
    Curr Med Chem; 2011; 18(26):4019-28. PubMed ID: 21824089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase.
    Fenaux M; Eng S; Leavitt SA; Lee YJ; Mabery EM; Tian Y; Byun D; Canales E; Clarke MO; Doerffler E; Lazerwith SE; Lew W; Liu Q; Mertzman M; Morganelli P; Xu L; Ye H; Zhang J; Matles M; Murray BP; Mwangi J; Zhang J; Hashash A; Krawczyk SH; Bidgood AM; Appleby TC; Watkins WJ
    Antimicrob Agents Chemother; 2013 Feb; 57(2):804-10. PubMed ID: 23183437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus.
    Le Pogam S; Kang H; Harris SF; Leveque V; Giannetti AM; Ali S; Jiang WR; Rajyaguru S; Tavares G; Oshiro C; Hendricks T; Klumpp K; Symons J; Browner MF; Cammack N; Nájera I
    J Virol; 2006 Jun; 80(12):6146-54. PubMed ID: 16731953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus.
    Hang JQ; Yang Y; Harris SF; Leveque V; Whittington HJ; Rajyaguru S; Ao-Ieong G; McCown MF; Wong A; Giannetti AM; Le Pogam S; Talamás F; Cammack N; Nájera I; Klumpp K
    J Biol Chem; 2009 Jun; 284(23):15517-29. PubMed ID: 19246450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of substituted N-phenylbenzenesulphonamides as a novel class of non-nucleoside hepatitis C virus polymerase inhibitors.
    May MM; Brohm D; Harrenga A; Marquardt T; Riedl B; Kreuter J; Zimmermann H; Ruebsamen-Schaeff H; Urban A
    Antiviral Res; 2012 Aug; 95(2):182-91. PubMed ID: 22580131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.